​

MaxCyte (MXCT) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

MXCT Stock Forecast

MaxCyte (MXCT) stock forecast, based on 5 Wall Street analysts, predicts a 12-month average price target of $6.00, with a high of $6.00 and a low of $6.00. This represents a 287.10% increase from the last price of $1.55.

$1 $2 $3 $4 $5 $6 High: $6 Avg: $6 Low: $6 Last Closed Price: $1.55

MXCT Stock Rating

MaxCyte stock's rating consensus is Buy, based on 5 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 3 Buy (60.00%), 2 Hold (40.00%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 5 0 2 3 Strong Sell Sell Hold Buy Strong Buy

MXCT Price Target Upside V Benchmarks

TypeNameUpside
StockMaxCyte287.10%
SectorHealthcare Stocks 15.45%
IndustryMedical Device Stocks20.18%

Price Target Trends

1M3M12M
# Anlaysts--1
Avg Price Target--$6.00
Last Closing Price$1.55$1.55$1.55
Upside/Downside--287.10%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Oct, 25-52--7
Sep, 25-52--7
Aug, 25-7---7
Jul, 25-6---6
Jun, 25-6---6
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Mar 12, 2025Mark MassaroBTIG$6.00$3.4772.91%287.10%
Mar 13, 2024Mark MassaroBTIG$8.00$4.1692.31%416.13%
Aug 14, 2022Mark MassaroBTIG$11.00$5.8787.39%609.68%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Aug 07, 2025William BlairMarket Performdowngrade
Mar 12, 2025BTIGBuyBuyhold
Oct 10, 2024Deutsche BankHoldBuyupgrade
Sep 24, 2024Cowen & Co.BuyBuyhold
May 03, 2024Deutsche BankHoldinitialise
Mar 13, 2024BTIGBuyBuyhold
Aug 14, 2022BTIGBuyBuyhold

Financial Forecast

EPS Forecast

Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-0.18$-0.22$-0.19$-0.37$-0.39----
Avg Forecast$-0.19$-0.22$-0.26$-0.40$-0.41$-0.38$-0.30$-0.27$-0.15
High Forecast$-0.18$-0.20$-0.24$-0.38$-0.40$-0.31$-0.28$-0.25$-0.14
Low Forecast$-0.21$-0.23$-0.27$-0.41$-0.42$-0.43$-0.32$-0.29$-0.16
Surprise %-5.26%--26.92%-7.50%-4.88%----

Revenue Forecast

$0 $30M $60M $90M $120M $150M Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$26.17M$33.89M$44.26M$41.29M$38.63M----
Avg Forecast$26.20M$33.38M$44.24M$39.06M$38.10M$46.31M$59.71M$99.30M$127.20M
High Forecast$27.44M$34.96M$46.22M$41.26M$40.25M$47.61M$63.08M$104.90M$134.38M
Low Forecast$24.99M$31.83M$42.52M$37.03M$36.13M$45.00M$56.62M$94.15M$120.61M
Surprise %-0.12%1.54%0.05%5.71%1.38%----

Net Income Forecast

$-45M $-38M $-31M $-24M $-17M $-10M Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-12.64M$-20.13M$-19.78M$-37.92M$-41.05M----
Avg Forecast$-20.10M$-22.35M$-26.39M$-40.79M$-42.54M$-39.20M$-30.74M$-27.88M$-15.49M
High Forecast$-18.89M$-21.00M$-25.05M$-38.75M$-41.52M$-32.51M$-28.67M$-26.00M$-14.45M
Low Forecast$-21.34M$-23.73M$-27.93M$-42.83M$-43.55M$-43.98M$-32.99M$-29.93M$-16.63M
Surprise %-37.11%-9.95%-25.04%-7.03%-3.48%----

MXCT Forecast FAQ

Is MaxCyte stock a buy?

MaxCyte stock has a consensus rating of Buy, based on 5 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 3 Buy, 2 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that MaxCyte is a favorable investment for most analysts.

What is MaxCyte's price target?

MaxCyte's price target, set by 5 Wall Street analysts, averages $6 over the next 12 months. The price target range spans from $6 at the low end to $6 at the high end, suggesting a potential 287.10% change from the previous closing price of $1.55.

How does MaxCyte stock forecast compare to its benchmarks?

MaxCyte's stock forecast shows a 287.10% upside, outperforming the average forecast for the healthcare stocks sector (15.45%) and outperforming the medical device stocks industry (20.18%).

What is the breakdown of analyst ratings for MaxCyte over the past three months?

  • October 2025: 0% Strong Buy, 71.43% Buy, 28.57% Hold, 0% Sell, 0% Strong Sell.
  • September 2025: 0% Strong Buy, 71.43% Buy, 28.57% Hold, 0% Sell, 0% Strong Sell.
  • August 2025: 0% Strong Buy, 100.00% Buy, 0% Hold, 0% Sell, 0% Strong Sell.

What is MaxCyte’s EPS forecast?

MaxCyte's average annual EPS forecast for its fiscal year ending in December 2025 is $-0.38, marking a -2.56% decrease from the reported $-0.39 in 2024. Estimates for the following years are $-0.3 in 2026, $-0.27 in 2027, and $-0.15 in 2028.

What is MaxCyte’s revenue forecast?

MaxCyte's average annual revenue forecast for its fiscal year ending in December 2025 is $46.31M, reflecting a 19.88% increase from the reported $38.63M in 2024. The forecast for 2026 is $59.71M, followed by $99.3M for 2027, and $127.2M for 2028.

What is MaxCyte’s net income forecast?

MaxCyte's net income forecast for the fiscal year ending in December 2025 stands at $-39.2M, representing a -4.52% decrease from the reported $-41.055M in 2024. Projections indicate $-30.739M in 2026, $-27.882M in 2027, and $-15.49M in 2028.